Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations

RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the appointments of Andrew Murphy, Ph.D., as Chief Scientific Officer and Jamie Lynne Hart, M.S., M.P.H., as Executive Director, Executive Operations. These appointments strengthen Opus Genetics’ scientific and operational capabilities as the Company advances its pipeline of gene therapies for inherited retinal diseases.

“As we continue to advance our clinical programs and expand our pipeline, strengthening our scientific leadership and operational capabilities is essential to supporting our next phase of growth,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “Andy brings deep expertise in gene therapy research, AAV vector development and translational science that we expect will be invaluable as we advance our programs toward important clinical milestones. Jamie brings extensive experience in executive operations and organizational coordination, and as well as significant experience in the ophthalmology sector, which we believe will help us execute effectively across our growing organization. We are pleased to welcome both to the Opus Genetics team.”